Enzalutamide

Type: Keyphrase
Name: Enzalutamide
First reported 13 hours ago - Updated 12 hours ago - 1 reports

Medivation Announces Change in Executive Management Team

SAN FRANCISCO, CA -- (Marketwired) -- 07/10/14 -- Medivation, Inc. (NASDAQ: MDVN) today announced Dawn Svoronos (formerly Graham) has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, chief executive officer and president ... [Published Pettinga Financial Advisors - 13 hours ago]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

AR-V7 Predicts Resistance to Enzalutamide and Abiraterone in Men With Castration-Resistant Prostate Cancer

Emmanuel S. Antonarakis, MDRole of AR-V7 in Prostate Cancer TherapyIf these results are supported by larger studies, detection of AR-V7 in circulating tumor cells may be used as a biomarker to predict resistance to enzalutamide, abiraterone, and AR-targeted ... [Published The ASCO Post - Jul 09 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

Urologists Face New Paradigm for Metastatic Prostate Cancer

Hello. I am Dr. Gerald Chodak, for Medscape. This week I want to talk about an important study [1] that was reported at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The study compared androgen deprivation therapy ... [Published American Journal of Public Health - Jul 09 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Progress in the treatment of advanced prostate cancer - Abstract

The androgen receptor (AR) is the most significant target for patients with metastatic castration-resistant prostate cancer (mCRPC).There is now irrefutable evidence that the AR axis is functional in most patients throughout the history of prostate cancer, ... [Published UroToday - Jul 04 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Prostate cancer Niclosamide jumps the hurdle of enzalutamide resistance

Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: Prostate cancer: Niclosamide jumps the hurdle of enzalutamide resistanceNEXT ARTICLE More From BioPortfolio on "Prostate cancer: Niclosamide jumps the hurdle of enzalutamide ... [Published BioPortfolio - Jul 01 2014]
First reported Jun 29 2014 - Updated Jun 30 2014 - 2 reports

[News] Enzalutamide in castration-resistant prostate cancer

Enzalutamide, an oral androgen-receptor inhibitor, prolongs the time until radiographic progression and improves overall survival in men with metastatic castration-resistant prostate cancer who have not previously undergone chemotherapy, according to ... [Published Lancet Oncology - Jun 30 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Updated Information on Prostate Cancer Drugs: Enzalutamide, Orteronel, and Cixutumumab

Treating Metastatic Castration-Resistant Prostate CancerEnzalutamide added to androgen-deprivation therapy provides clinically meaningful benefits to men with metastatic castration-resistant prostate cancer.—Andrew J. Armstrong, MD, ScM, FACPThree separate ... [Published The ASCO Post - Jun 25 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

Prostate cancer An enzalutamide antiandrogen withdrawal syndrome

Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: Prostate cancer: An enzalutamide antiandrogen withdrawal syndromeNEXT ARTICLE More From BioPortfolio on "Prostate cancer: An enzalutamide antiandrogen withdrawal syndrome"Search ... [Published BioPortfolio - Jun 24 2014]
First reported Jun 23 2014 - Updated Jun 24 2014 - 4 reports

Targeting Androgen Receptors May Be Possible for Some Breast Cancers

the Chemotherapy Advisor take:Some patients with estrogen receptor–positive breast cancer experience treatment failure when using estrogen-blocking drugs. According to a study presented at the joint meeting of the International Society of Endocrinology ... [Published Chemotherapy Advisor - Jun 24 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

Practical guide to the use of enzalutamide - Abstract

INTRODUCTION: We summarize the development, definitive trials, and practical use of enzalutamide for practicing urologists and medical oncologists.The care paradigm for patients with metastatic castration resistant prostate cancer (mCRPC) is a changing ... [Published UroToday - Jun 18 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 2 reports

Xtandi Found to Delay Need for Chemotherapy in Metastatic Prostate Cancer Patients

In results of a phase III trial reported at the 2014 American Society of Clinical Oncologists, treatment with Xtandi® (enzalutamide) was found to significantly delay the need for chemotherapy in metastatic prostate cancer patients previously treated. ... [Published BioPortfolio - Jun 16 2014]
First reported Jun 12 2014 - Updated Jun 12 2014 - 2 reports

Prostate cancer drug delivers benefits before chemotherapy

By a News Reporter-Staff News Editor at Biotech Week -- A comprehensive analysis of the study's results - published in June 1 online edition of the New England Journal of Medicine and to be presented at the American Society of Clinical Oncology (ASCO) ... [Published HispanicBusiness.com - Jun 12 2014]

Quotes

...for her years of service to Medivation and wish her the best," said David Hung, M D , president and chief executive officer of Medivation Inc. "We are fortunate to have Dawn Svoronos, a seasoned executive with significant commercial expertise, step in on an interim basis to lead Medivation's commercial operations."
"Aragon was acquired last year by Johnson & Johnson JNJ/NYSE, Not Rated) for $650mm plus up to $350mm in milestones. Roche paid a staggering $725mm upfront for Seragon, with an additional $1bn payable in milestones alone upon achievement of pre-specified development- and sales-related thresholds. Seragon is developing androgen receptor antagonists in hormone receptor-positive breast cancer and endometrial cancer. Its lead candidate, ARN-810, is currently only in Phase 1 testing. XTANDI™, in contrast, is not only an approved agent but is also in Phase 2 testing for breast cancer in at least four different studies. The drug is also being tested in patients with ovarian, primary peritoneal or fallopian tube cancer."
Dr. Mann agreed that enzalutamide would "provide another option for men with castrate-resistant prostate cancer prior to receiving chemotherapy" if the FDA were to approve it for this indication
...up the disease to say, for example, that only the high AR expressing subtype should be treated with anti-androgen receptor therapies," Barton says. "But what we show is that even triple negative breast cancers with lower androgen receptor expression critically depend on the androgen receptor and may benefit from anti-androgen receptor therapy. Our results suggest that anti-androgen receptor therapy may benefit a larger percentage of triple negative breast cancers than previously thought."

More Content

All (143) | News (111) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Medivation Announces Change in Executive Manage... [Published Pettinga Financial Advisors - 13 hours ago]
Medivation Announces Change in Executive Manage... [Published Franklin Credit Management Corporation - 13 hours ago]
AR-V7 Predicts Resistance to Enzalutamide and A... [Published The ASCO Post - Jul 09 2014]
Urologists Face New Paradigm for Metastatic Pro... [Published American Journal of Public Health - Jul 09 2014]
Progress in the treatment of advanced prostate ... [Published UroToday - Jul 04 2014]
Patient-reported outcome labeling claims and me... [Published 7thSpace - Jul 04 2014]
Aegis Capital Believes Seragon Deal Underscores... [Published Benzinga.com - Jul 02 2014]
Prostate cancer Niclosamide jumps the hurdle of... [Published BioPortfolio - Jul 01 2014]
[News] Enzalutamide in castration-resistant pro... [Published Lancet Oncology - Jun 30 2014]
Enzalutamide Improves Survival in Patients with... [Published National Cancer Institute - Jun 29 2014]
Development of cabozantinib for the treatment o... [Published UroToday - Jun 28 2014]
Updated Information on Prostate Cancer Drugs: E... [Published The ASCO Post - Jun 25 2014]
Prostate cancer An enzalutamide antiandrogen wi... [Published BioPortfolio - Jun 24 2014]
Prostate cancer Cabazitaxelthe taxane of choice... [Published BioPortfolio - Jun 24 2014]
Docetaxel plus ADT improved OS in metastatic pr... [Published Orthopedics Today - Jun 24 2014]
Targeting Androgen Receptors May Be Possible fo... [Published Chemotherapy Advisor - Jun 24 2014]
Study Shows Wider Benefit for Anti-Androgen Rec... [Published P&T Community - Jun 23 2014]
Blood Test Predicts Resistance to Enzalutamide ... [Published OncLive - Jun 23 2014]
Anti-androgen therapy for triple-negative breas... [Published EurekAlert! - Jun 23 2014]
Possible new weapon found for fighting some typ... [Published EurekAlert! - Jun 23 2014]
Pharma gets social: did digital opinion leaders... [Published pharmaphorum - Jun 23 2014]
Takeda drops prostate cancer drug in phase III [Published PMLive - Jun 20 2014]
Takeda terminates prostate cancer drug orteronel [Published Pharma Times - Jun 20 2014]
Forum Post: RE: Keep taking the tablets. [Published Macmillan Cancer Support - Jun 19 2014]
Two Cancer Stocks Take Shots On Goal: Echo He [Published Seeking Alpha - Jun 19 2014]
How to approach sequencing therapy in patients ... [Published UroToday - Jun 19 2014]
3 Terrific Reasons To Buy Dendreon [Published Seeking Alpha - Jun 18 2014]
New England Journal of Medicine Publishes Resul... [Published Pharmacy Choice - Jun 18 2014]
Combination Hormone Therapy Appears Safe and Ef... [Published CancerConnect.com - Jun 18 2014]
Practical guide to the use of enzalutamide - Ab... [Published UroToday - Jun 18 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Articles Most Widely Covered in the Press - Jun 10 2014]
Prostate cancer is the most commonly diagnosed cancer and the sixth leading cause of cancer-related death among men worldwide.1 Strategies to block androgen-receptor signaling have formed the backbone of prostate-cancer therapy since the first description ...
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Viewed Articles - Week - Jun 04 2014]
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Emailed Articles - Jun 04 2014]
New Drug May Boost Survival for Advanced Prosta... [Published MedlinePlus Health News - Jun 02 2014]
Enzalutamide also delays need for chemotherapy, researchers report Source: HealthDayRelated MedlinePlus Pages: Medicines , Prostate Cancer ...
New England Journal of Medicine Publishes Resul... [Published PR Newswire: Entertainment & Media - Jun 01 2014]
NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced the online publication in the New England ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Astellas Announces Marketing Approval in Japan ... [Published Financial Services - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.